Effects of dehydroepiandrosterone, Premarin and Acolbifene on histomorphology and sex steroid receptors in the rat vagina

Berger, Louise; El‐Alfy, Mohamed; Martel, Céline; Labrie, Fernand

doi:10.1016/j.jsbmb.2005.02.018

Cited by 57 publications

(43 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similarly, treatment of rats with progestational compounds, such as progesterone receptor agonists or glucocorticoid receptor agonists with low selectivity against the progesterone receptor, can cause vaginal mucification (Gopinath et al, 1987). Vaginal mucification can also be observed following treatments altering the progesterone:estradiol ratio in favor of progesterone (Daly and Kramer, 1998;Yuan and Foley, 2002;Berger et al, 2005). Vaginal mucification is not expected with compounds that induce hypoprolactinemia.…”

Section: Vaginal Mucification and Increased Number Of Diestrus Vaginamentioning

confidence: 99%

Identification of drug‐induced hyper‐ or hypoprolactinemia in the female rat based on general and reproductive toxicity study parameters

Rehm¹,

Stanislaus²,

Wier³

2007

Birth Defects Research Pt B

View full text Add to dashboard Cite

Observations associated with drug-induced hyper- or hypoprolactinemia in rat toxicology studies may be similar and include increased ovarian weight due to increased presence of corpora lutea. Hyperprolactinemia may be distinguished if mammary gland hyperplasia with secretion and/or vaginal mucification is observed. Reproductive toxicity study endpoints can differentiate hyper- from hypoprolactinemia based on their differential effects on estrous cycles, mating, and fertility. Although the manifestations of hyper- and hypoprolactinemia in rats generally differ from that in humans, mechanisms of drug-related changes in prolactin synthesis/release can be conserved across species and pathologically increased or decreased prolactin levels may compromise some aspect of reproductive function in all species.

show abstract

Section: Vaginal Mucification and Increased Number Of Diestrus Vaginamentioning

confidence: 99%

Identification of drug‐induced hyper‐ or hypoprolactinemia in the female rat based on general and reproductive toxicity study parameters

Rehm¹,

Stanislaus²,

Wier³

2007

Birth Defects Research Pt B

View full text Add to dashboard Cite

show abstract

“…The OVX rat vaginal response to DHEA treatment has been well documented in our previous study [30]. From that study, we know that DHEA induces a major predominant androgenic effect, which translates mainly into epithelial mucification and an increase of collagen compactness and fineness.…”

Section: Morphology Serum Metabolites and Total Body Weightmentioning

confidence: 52%

“…Each vagina was divided into eight equal cross-segments, as described [30], while the uterus was divided into four segments (see the legend of Fig. 1).…”

Section: Histological Proceduresmentioning

confidence: 99%

“…In a previous experiment, we have used the ovariectomized (OVX) rat model to assess the effects on the vaginal mucosa of a pharmacological dose of micronized DHEA applied on the dorsal skin [30]. In that study, reversal of vaginal epithelial atrophy with formation of a thick mucified epithelium-a typical androgenic effect in the rodent [31,32], was observed.…”

Section: Introductionmentioning

confidence: 99%

“…Furthermore, since the rodent tissues are known to possess the steroidogenic enzymesincluding 17␤-hydroxysteroid dehydrogenases and aromatase -required for local transformation of DHEA into androgens and estrogens [37], and since the morphological effects of these hormones on the vaginal mucosa have been well described [30], the OVX rat is an appropriate model for the study of the effects of intravaginal DHEA on the three layers of the vaginal wall.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Effects of intravaginal dehydroepiandrosterone on vaginal histomorphology, sex steroid receptor expression and cell proliferation in the rat

Berger

El‐Alfy

Labrie

2008

The Journal of Steroid Biochemistry and Molecular Biology

View full text Add to dashboard Cite

Evolution of Selective Estrogen and Androgen Receptor Modulators: Status of Current Therapy and New Drug Development

Wurz

DeGregorio

2011

Pharmaceutical Sciences Encyclopedia

View full text Add to dashboard Cite

Prior to the discovery of nonsteroidal selective estrogen and androgen receptor modulators (SERMs and SARMs), the only available treatment modalities for conditions such as menopausal symptoms and postmenopausal osteoporosis in women, and the symptoms associated with hypogonadism in men, were steroid based. As this chapter will discuss, recent clinical trial data have shown that the long‐term use of hormone replacement therapy in postmenopausal women is associated with an increased risk of breast cancer and may increase the risk of coronary heart disease and dementia, contrary to the results of previous observational studies. There are also concerns that androgen replacement therapy in hypogonadal men may pose a risk to prostate health, in addition to the difficulties inherent with the delivery of steroidal androgens. Thus, there is now great interest in developing nonsteroidal, orally bioavailable therapies, that is, SERMs and SARMs, that can provide the respective benefits of estrogens and androgens while minimizing their associated side effects.

show abstract

Effects of dehydroepiandrosterone, Premarin and Acolbifene on histomorphology and sex steroid receptors in the rat vagina

Cited by 57 publications

References 53 publications

Identification of drug‐induced hyper‐ or hypoprolactinemia in the female rat based on general and reproductive toxicity study parameters

Identification of drug‐induced hyper‐ or hypoprolactinemia in the female rat based on general and reproductive toxicity study parameters

Effects of intravaginal dehydroepiandrosterone on vaginal histomorphology, sex steroid receptor expression and cell proliferation in the rat

Evolution of Selective Estrogen and Androgen Receptor Modulators: Status of Current Therapy and New Drug Development

Contact Info

Product

Resources

About